WillItSurvive
No grouping · United States

Lakewood-Amedex Biotherapeutics Inc.

Clinical-stage biotech testing Bisphosphocin, an antibiotic for infected diabetic foot ulcers.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Next 10-Q cash update or emergency financing round
The call

Lakewood-Amedex is a five-employee antibiotic developer running on fumes, racing an emergency financing round against a Phase 2a trial it may not live to finish.

Lakewood-Amedex is a very early-stage drug company developing a new antibiotic called Bisphosphocin to fight hard-to-treat infections. The company has a real scientific advantage and the FDA is backing its testing plan, but those things do not solve the immediate problem: it has almost no money left (around $11,700 to $236,000 depending on accounting) while spending roughly $420,000 every three months, and the whole antibiotic business is extremely hard to make money in because hospitals only use new antibiotics as a last resort and insurers pay poorly. The one thing that could change everything is an emergency funding deal; if the company can raise enough cash on acceptable terms, it buys time to finish its next round of human testing, but if funding comes on very harsh terms (huge price cut on shares), today's investors get heavily diluted or wiped out.

Why
01
AI pressure: None apparent. AI drug-discovery tools speed up rivals' pipelines, but LABT's problem right now is cash, not competition from AI models. Could AI do the core job? Unlikely.
02
Bigger players: GSK, Shionogi, Otsuka. These are nearly the only large drugmakers still funding antibiotics; they could partner with or bypass a five-person company like LABT. Could a giant copy it? Probably.
03
What protects it. A Bisphosphocin patent and an FDA pathway for infectious disease drugs, but neither buys time against a near-empty bank account.
What would change this call
Lakewood-Amedex announces a financing round or S-1/S-3 filing within the next two quarters. Shows whether the company can raise cash before running out, or faces near-term insolvency.
Phase 2a trial in infected diabetic foot ulcers begins dosing and reports interim data. Shows whether the Bisphosphocin drug candidate is advancing or stalling for lack of funds.
A partnership or licensing deal with a major pharma such as GSK, Shionogi, or Otsuka is announced. Would show outside validation and non-dilutive capital, offsetting sector funding collapse.
Key numbers
  • Cash fell to about $11,700 vs over $3M in liabilities (Jul 22, 2026)
  • Stock dropped about 96%, from $73.50 to $2.64 (Jul 24, 2026)
  • 2025 net loss was $3,847,637 (2025 FY)
Named risks
  • Going-concern liquidity crisis: cash as low as $11,700 vs $3M+ liabilities as of Jul 22, 2026. Severity: high
  • Near-certain dilutive financing needed given ~$420,000/quarter burn. Severity: high
  • 9,375,000 share Series C conversion overhang creates ongoing dilution pressure. Severity: medium
  • AMR sector's broken commercial economics has sunk peers with approved drugs (Melinta, Achaogen, Tetraphase). Severity: high
  • Five-person team outsourcing Phase 2a trial execution to CRO raises execution risk. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
GSKcontestingNamed among only majors still funding novel antibiotics per Mar 9, 2026 AMR Benchmark
OtsukacontestingOne of few large pharma firms still active in AMR R&D as of Mar 2026
ShionogicontestingContinues AMR investment while most big pharma exited, per Mar 2026 benchmark
Melinta, Achaogen, Tetraphase (historical peers)losing toAll had approved antibiotics yet still collapsed, illustrating AMR commercial economics risk
Questions people ask
Is Lakewood-Amedex Biotherapeutics profitable in 2026?
No. LABT is pre-revenue and clinical-stage, with a 2025 net loss of $3,847,637 and year-end 2025 cash of just $236,400. By July 22, 2026 cash was reported as low as $11,700 against over $3 million in liabilities, signaling acute going-concern risk.
Is Lakewood-Amedex at risk of running out of cash?
Yes. Quarterly cash burn is roughly $420,000 as of Q1 2026, and reported cash fell to about $11,700 by July 22, 2026 against $3M+ in liabilities. Its last raise, a $7.5 million Series C in January 2026, appears largely spent with no new capital from the April 2026 direct listing.
Who owns Lakewood-Amedex Biotherapeutics (LABT)?
LABT is a standalone Nasdaq-listed company with no parent. HPW Investments Holding Ltd. disclosed beneficial ownership of 3,435,501 shares, or 24.04%, in a June 2026 Schedule 13G filing, making it the largest known shareholder.
Who are Lakewood-Amedex's biggest competitors?
In antimicrobial resistance R&D, GSK, Otsuka, and Shionogi are named by the Access to Medicine Foundation's 2026 AMR Benchmark (March 9, 2026) as among the few major pharma companies still funding novel antibiotics, dwarfing LABT's five-person team and thin capital base.
Could AI replace what Lakewood-Amedex does?
No. LABT's value rests on composition-of-matter patents for its Bisphosphocin compounds, wet-lab resistance data, and a regulated Phase 2a trial pathway with CRO partner PERI, announced May 12, 2026. These require FDA-regulated clinical infrastructure that AI cannot substitute for.
What is Lakewood-Amedex's lead drug candidate?
Nu-3, a topical Bisphosphocin gel for infected diabetic foot ulcers. On July 15, 2026 the company announced dose selection of 2%, 5%, and 10% gel concentrations based on preclinical safety data ahead of a planned Phase 2a trial.
Timeline
  • 2026-07-15Announced Phase 2a dose selection (2%, 5%, 10% Nu-3 gel) and composition-of-matter patent for Bisphosphocins
  • 2026-07-07Publicly supported reintroduction of the PASTEUR Act to address AMR sector economics
  • 2026-06-23Zacks Small Cap Research initiated coverage with a $12 price target
  • 2026-06-19Executed 1-for-10 reverse stock split, cutting authorized shares to 12,500,000
  • 2026-05-18Announced positive cGMP-scale manufacturing data for Nu-3 drug substance and gel
  • 2026-05-12Engaged CRO PERI to run Phase 2 clinical trial
  • 2026-04-23Completed Nasdaq direct listing under ticker LABT, raising no new capital
  • 2026-01Closed $7.5 million Series C Convertible Preferred Stock private placement
  • 2025-06Renamed from Lakewood-Amedex Inc. to Lakewood-Amedex Biotherapeutics, Inc.
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources